OSLO--(BUSINESS WIRE)-- Regulatory News: DiaGenic ASA (OSE:DIAG.OL - News): The Chief Executive Officer, Erik Christensen, MD PhD, has notified the Board of Directors that he would like to resign from his position with effect from 17 April 2012. Erik Christensen will continue to provide consultative support to the company on partner interactions, licensing and other business activities . Chairman of the Board of Directors of DiaGenic ASA, Henrik Lund MD PhD, has been constituted as the Chief Executive Officer from and including 17 April 2012 until a new Chief Executive Officer is employed. Henrik Lund will from the same date leave the Board of Directors. Deputy Chairman of the Board of Directors, Ingrid Wiik, will act as Chairman of the Board of Directors until the annual general meeting of the company to be held on 5 June 2012.
Erik Christensen has been the Chief Executive Officer of DiaGenic since 2007, and has managed the company during development of blood based diagnostic tests for Alzheimer’s disease and breast cancer. Erik Christensen has managed the company during the research and development of the world’s first blood based test for detection of early Alzheimer’s disease in collaboration with Pfizer, US and established research collaboration with GE Healthcare, US for the development of a blood based test supporting PET brain imaging in detection of Alzheimer`s disease.
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer’s disease has been identified. The company has been granted patents in Europe and US and is listed on the Oslo Stock Exchange. For more information, please visit: www.diagenic.com
This information was brought to you by Cision http://www.cisionwire.com
Contact:
DiaGenic ASA
Henrik Lund: +47 90 97 12 19
